Serveur d'exploration autour de Joseph Jankovic

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Identifieur interne : 000012 ( PascalFrancis/Curation ); précédent : 000011; suivant : 000013

Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients

Auteurs : Joseph Jankovic [États-Unis]

Source :

RBID : Pascal:01-0069947

Descripteurs français

English descriptors

Abstract

Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.
pA  
A01 01  1    @0 0362-5664
A02 01      @0 CLNEDB
A03   1    @0 Clin. neuropharmacol.
A05       @2 23
A06       @2 5
A08 01  1  ENG  @1 Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
A11 01  1    @1 JANKOVIC (Joseph)
A14 01      @1 Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 1 aut.
A20       @1 252-261
A21       @1 2000
A23 01      @0 ENG
A43 01      @1 INIST @2 16720 @5 354000093580530030
A44       @0 0000 @1 © 2001 INIST-CNRS. All rights reserved.
A45       @0 113 ref.
A47 01  1    @0 01-0069947
A60       @1 P
A61       @0 A
A64 01  1    @0 Clinical neuropharmacology
A66 01      @0 USA
C01 01    ENG  @0 Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.
C02 01  X    @0 002B02B06
C03 01  X  FRE  @0 Parkinson maladie @5 01
C03 01  X  ENG  @0 Parkinson disease @5 01
C03 01  X  SPA  @0 Parkinson enfermedad @5 01
C03 02  X  FRE  @0 Lévodopa @5 04
C03 02  X  ENG  @0 Levodopa @5 04
C03 02  X  SPA  @0 Levodopa @5 04
C03 03  X  FRE  @0 Antiparkinsonien @5 05
C03 03  X  ENG  @0 Antiparkinson agent @5 05
C03 03  X  SPA  @0 Antiparkinsoniano @5 05
C03 04  X  FRE  @0 Sélégiline @2 NK @2 FR @5 07
C03 04  X  ENG  @0 Selegiline @2 NK @2 FR @5 07
C03 04  X  SPA  @0 Selegilina @2 NK @2 FR @5 07
C03 05  X  FRE  @0 IMAO B @5 08
C03 05  X  ENG  @0 MAO B inhibitor @5 08
C03 05  X  SPA  @0 IMOA B @5 08
C03 06  X  FRE  @0 Récepteur dopaminergique @5 10
C03 06  X  ENG  @0 Dopamine receptor @5 10
C03 06  X  SPA  @0 Receptor dopaminérgico @5 10
C03 07  X  FRE  @0 Agoniste @5 11
C03 07  X  ENG  @0 Agonist @5 11
C03 07  X  SPA  @0 Agonista @5 11
C03 08  X  FRE  @0 Transmission cholinergique @5 12
C03 08  X  ENG  @0 Cholinergic transmission @5 12
C03 08  X  SPA  @0 Transmisión colinérgica @5 12
C03 09  X  FRE  @0 Inhibiteur enzyme @5 13
C03 09  X  ENG  @0 Enzyme inhibitor @5 13
C03 09  X  SPA  @0 Inhibidor enzima @5 13
C03 10  X  FRE  @0 Homme @5 16
C03 10  X  ENG  @0 Human @5 16
C03 10  X  SPA  @0 Hombre @5 16
C03 11  X  FRE  @0 Traitement @5 17
C03 11  X  ENG  @0 Treatment @5 17
C03 11  X  SPA  @0 Tratamiento @5 17
C03 12  X  FRE  @0 Chimiothérapie @5 18
C03 12  X  ENG  @0 Chemotherapy @5 18
C03 12  X  SPA  @0 Quimioterapia @5 18
C03 13  X  FRE  @0 Essai thérapeutique contrôlé @5 19
C03 13  X  ENG  @0 Controlled therapeutic trial @5 19
C03 13  X  SPA  @0 Ensayo terapéutico controlado @5 19
C03 14  X  FRE  @0 Activité biologique @5 20
C03 14  X  ENG  @0 Biological activity @5 20
C03 14  X  SPA  @0 Actividad biológica @5 20
C03 15  X  FRE  @0 Article synthèse @5 21
C03 15  X  ENG  @0 Review @5 21
C03 15  X  SPA  @0 Artículo síntesis @5 21
C03 16  X  FRE  @0 Catechol O-methyltransferase @2 FE @5 80 @6 Catechol «O»-methyltransferase
C03 16  X  ENG  @0 Catechol O-methyltransferase @2 FE @5 80 @6 Catechol «O»-methyltransferase
C03 16  X  SPA  @0 Catechol O-methyltransferase @2 FE @5 80 @6 Catechol «O»-methyltransferase
C07 01  X  FRE  @0 Système nerveux pathologie @5 37
C07 01  X  ENG  @0 Nervous system diseases @5 37
C07 01  X  SPA  @0 Sistema nervioso patología @5 37
C07 02  X  FRE  @0 Système nerveux central pathologie @5 38
C07 02  X  ENG  @0 Central nervous system disease @5 38
C07 02  X  SPA  @0 Sistema nervosio central patología @5 38
C07 03  X  FRE  @0 Encéphale pathologie @5 39
C07 03  X  ENG  @0 Cerebral disorder @5 39
C07 03  X  SPA  @0 Encéfalo patología @5 39
C07 04  X  FRE  @0 Extrapyramidal syndrome @5 40
C07 04  X  ENG  @0 Extrapyramidal syndrome @5 40
C07 04  X  SPA  @0 Extrapiramidal síndrome @5 40
C07 05  X  FRE  @0 Maladie dégénérative @5 41
C07 05  X  ENG  @0 Degenerative disease @5 41
C07 05  X  SPA  @0 Enfermedad degenerativa @5 41
C07 06  X  FRE  @0 Methyltransferases @2 FE
C07 06  X  ENG  @0 Methyltransferases @2 FE
C07 06  X  SPA  @0 Methyltransferases @2 FE
C07 07  X  FRE  @0 Transferases @2 FE
C07 07  X  ENG  @0 Transferases @2 FE
C07 07  X  SPA  @0 Transferases @2 FE
C07 08  X  FRE  @0 Enzyme
C07 08  X  ENG  @0 Enzyme
C07 08  X  SPA  @0 Enzima
N21       @1 043

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:01-0069947

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title>
<author>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">01-0069947</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0069947 INIST</idno>
<idno type="RBID">Pascal:01-0069947</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000154</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000012</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</title>
<author>
<name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint>
<date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Biological activity</term>
<term>Catechol O-methyltransferase</term>
<term>Chemotherapy</term>
<term>Cholinergic transmission</term>
<term>Controlled therapeutic trial</term>
<term>Dopamine receptor</term>
<term>Enzyme inhibitor</term>
<term>Human</term>
<term>Levodopa</term>
<term>MAO B inhibitor</term>
<term>Parkinson disease</term>
<term>Review</term>
<term>Selegiline</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Antiparkinsonien</term>
<term>Sélégiline</term>
<term>IMAO B</term>
<term>Récepteur dopaminergique</term>
<term>Agoniste</term>
<term>Transmission cholinergique</term>
<term>Inhibiteur enzyme</term>
<term>Homme</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
<term>Essai thérapeutique contrôlé</term>
<term>Activité biologique</term>
<term>Article synthèse</term>
<term>Catechol O-methyltransferase</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0362-5664</s0>
</fA01>
<fA02 i1="01">
<s0>CLNEDB</s0>
</fA02>
<fA03 i2="1">
<s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05>
<s2>23</s2>
</fA05>
<fA06>
<s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA20>
<s1>252-261</s1>
</fA20>
<fA21>
<s1>2000</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>16720</s2>
<s5>354000093580530030</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>113 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>01-0069947</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Advances in the understanding of basal ganglia circuitry and its altered function in disease states such as Parkinson's disease (PD), coupled with new insights into the mechanisms of cell death and new findings from therapeutic clinical trials, are being translated into clinical practice. Although levodopa (L-Dopa) remains the most effective drug in the symptomatic treatment of PD, the emergence of side effects, particularly motor fluctuations and dyskinesias, limits its usefulness. Therefore, many parkinsonologists now advocate therapeutic strategies designed to delay the onset of L-Dopa therapy to delay the onset of L-Dopa-related motor complications. The therapeutic approach to PD, however, must be individualized and based on factors such as age of the patient, stage of the disease, and degree of interference of the symptoms with social and occupational functioning, associated symptoms such as cognitive impairment, and response to treatment. This review summarizes the current therapeutic strategies, but it is important to emphasize that the treatment recommendations must be tailored to the needs of individual patients.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Lévodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Levodopa</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Antiparkinsonien</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Antiparkinson agent</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Antiparkinsoniano</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Sélégiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Selegiline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Selegilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>IMAO B</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>MAO B inhibitor</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>IMOA B</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Récepteur dopaminergique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Dopamine receptor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Receptor dopaminérgico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Agoniste</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Agonista</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Transmission cholinergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Cholinergic transmission</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Transmisión colinérgica</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Inhibiteur enzyme</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Enzyme inhibitor</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Inhibidor enzima</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Homme</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Human</s0>
<s5>16</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Chimiothérapie</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Chemotherapy</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA">
<s0>Quimioterapia</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE">
<s0>Essai thérapeutique contrôlé</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG">
<s0>Controlled therapeutic trial</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA">
<s0>Ensayo terapéutico controlado</s0>
<s5>19</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE">
<s0>Activité biologique</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG">
<s0>Biological activity</s0>
<s5>20</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA">
<s0>Actividad biológica</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE">
<s0>Article synthèse</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG">
<s0>Review</s0>
<s5>21</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA">
<s0>Artículo síntesis</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE">
<s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="16" i2="X" l="ENG">
<s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC03 i1="16" i2="X" l="SPA">
<s0>Catechol O-methyltransferase</s0>
<s2>FE</s2>
<s5>80</s5>
<s6>Catechol «O»-methyltransferase</s6>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Methyltransferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Transferases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Enzyme</s0>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Enzyme</s0>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Enzima</s0>
</fC07>
<fN21>
<s1>043</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000012 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000012 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:01-0069947
   |texte=   Parkinson's disease therapy : Tailoring choices for early and late disease, young and old patients
}}

Wicri

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024